Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft[3].
Brontictuzumab (20 mg/kg, i.p., every 4days) inhibits DLL4 induced activation of Notch1 in MCL model[2].
| Animal Model: | T-ALL xenograft[3] |
| Dosage: | 15 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), twice weekly. |
| Result: | Inhibited tumor growth and reduced the size of the spleen.
Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.
|
| Animal Model: | NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo[2] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth. |
